Management ChangeApr 24, 2026, 05:06 PM
Indaptus Therapeutics Appoints Two New Independent Directors
AI Summary
Indaptus Therapeutics, Inc. announced the appointment of Mr. Tim Ruan and Dr. Johnny Fox Arrowsmith as independent directors to its Board, effective April 22, 2026. Mr. Ruan, 40, brings significant experience as CFO of Ocumension Therapeutics and from senior roles at Goldman Sachs and Morgan Stanley. This filing is an amendment to clarify that Dr. Arrowsmith's legal name is Johnny Fox Arrowsmith, though he uses Yi Zhang professionally.
Key Highlights
- Indaptus Therapeutics appointed Tim Ruan and Dr. Johnny Fox Arrowsmith as independent directors.
- Appointments were effective April 22, 2026.
- Tim Ruan, 40, is CFO of Ocumension Therapeutics, with prior roles at Goldman Sachs and Morgan Stanley.
- Dr. Arrowsmith's legal name was clarified from Yí Zhang to Johnny Fox Arrowsmith.
Price Impact
More from INDP